Monoclonal antibody · Inhibitor of tumor necrosis factor alpha (TNF) · developed by Centocor
ApprovedFDA, Aug 1998
1Registered trials
What is Infliximab?
Infliximab is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane forms of tumor necrosis factor alpha (TNFα), blocking its binding to receptors and neutralizing its pro-inflammatory activity. It is used in inflammatory diseases including Crohn's disease, ulcerative colitis, and rheumatoid arthritis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 11, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.